3 active not recruiting, 2 completed, 2 recruiting. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
Follow 177Lu-PSMA: new trials by email Literature Review of 177Lu-PSMA trials Research Report on 177Lu-PSMA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy 177Lu-PSMA - Oligometastatic Prostate Cancer | Phase 2 | Recruiting | Peter MacCallum Cancer Centre, Australia | 92 | 2023-12-14 | 2025-07-11 |
| Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) [177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy - Prostate Cancer | Phase 2 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 70 | 2023-06-27 | 2025-12-03 |
| Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) 177Lu-PSMA - Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive | Phase 2 | Completed | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 143 | 2022-10-25 | 2025-01-08 |
| ProsTIC Registry of Men Treated With PSMA Theranostics 177Lu-PSMA - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 500 | 2021-05-19 | 2026-05-14 | |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy 177Lu-PSMA-617 - Prostatic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-08-06 | 2024-11-08 |
| PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) Pembrolizumab, 177Lu-PSMA - Metastatic Castration Resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Peter MacCallum Cancer Centre, Australia | 37 | 2019-07-12 | 2023-07-28 |
| 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer Olaparib, 177Lu-PSMA - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 70 | 2019-07-09 | 2025-05-14 |
Peter MacCallum Cancer Centre, Australia (5) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2)
Australia (5) · Italy (2) · Israel (1)
Shahneen Sandhu (2) · Declan Murphy (1) · Dr Aravind S. Ravi Kumar (1) · Federica Matteucci (1) · Giovanni Paganelli (1) · John Violet (1) · Michael S Hofman (1)
PMID 40610228, PMID 32430583, PMID 34333554, PMID 37891072, PMID 41067860, PMID 41926961